Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) FCF Margin (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of FCF Margin data on record, last reported at 7.15% in Q4 2025.

  • For Q4 2025, FCF Margin fell 1625.0% year-over-year to 7.15%; the TTM value through Dec 2025 reached 4.48%, up 1578.0%, while the annual FY2025 figure was 4.48%, 1578.0% up from the prior year.
  • FCF Margin reached 7.15% in Q4 2025 per APLS's latest filing, down from 23.62% in the prior quarter.
  • Across five years, FCF Margin topped out at 23.62% in Q3 2025 and bottomed at 20695.99% in Q2 2021.
  • Average FCF Margin over 5 years is 1446.16%, with a median of 153.2% recorded in 2023.
  • The widest YoY moves for FCF Margin: up 2003789bps in 2022, down -43816bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 186.63% in 2021, then crashed by -235bps to 624.78% in 2022, then soared by 89bps to 66.93% in 2023, then skyrocketed by 114bps to 9.1% in 2024, then plummeted by -179bps to 7.15% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 7.15% in Q4 2025, 23.62% in Q3 2025, and 2.46% in Q2 2025.